Payment overview · 2025
General Payments
$46.45
3 reported records · 3 companies
Healthcare provider profile · identity verified
Enrique A Leal, MD
Allopathic & Osteopathic Physicians|Family Medicine · SWEENY, TX · NPI 1972664076
Verified facts
What the public records show
CMS Open Payments records show Enrique A Leal, MD received $46.45 in general payments during 2025 across 3 reported records.
PBG PUERTO RICO LLC accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $19.07 | 41.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.87 | 36.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $10.51 | 22.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $46.45 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYNDAQEL Normalized: vyndaqel |
Drug | PBG PUERTO RICO LLC | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $10.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 425 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 87 |
| Lisinopril | Lisinopril | 314 | 99 |
| Gabapentin | Gabapentin | 216 | 70 |
| Metformin Hcl | Metformin Hcl | 199 | 64 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 168 | 117 |
| Furosemide | Furosemide | 157 | 58 |
| Losartan Potassium | Losartan Potassium | 145 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 62 |
| Eliquis | Apixaban | 126 | 39 |
| Sertraline Hcl | Sertraline Hcl | 123 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 44 |
| Ozempic | Semaglutide | 111 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 32 |
| Carvedilol | Carvedilol | 98 | 31 |
| Omeprazole | Omeprazole | 96 | 40 |
| Methylprednisolone | Methylprednisolone | 95 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 41 |
| Potassium Chloride | Potassium Chloride | 80 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 22 |
| Alendronate Sodium | Alendronate Sodium | 63 | 23 |
| Trazodone Hcl | Trazodone Hcl | 60 | 25 |
| Montelukast Sodium | Montelukast Sodium | 58 | 21 |
| Clonazepam | Clonazepam | 55 | 13 |
| Buspirone Hcl | Buspirone Hcl | 53 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 18 |
| Glipizide | Glipizide | 49 | 18 |
| Spironolactone | Spironolactone | 49 | 21 |
| Allopurinol | Allopurinol | 47 | 18 |
| Memantine Hcl | Memantine Hcl | 45 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 34 |
| Donepezil Hcl | Donepezil Hcl | 41 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 15 |
| Simvastatin | Simvastatin | 41 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 23 |
| Nifedipine Er | Nifedipine | 39 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 12 |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 24 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Famotidine | Famotidine | 34 | 11 |
| Enulose | Lactulose | 31 | 14 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 31 | 30 |
| Ezetimibe | Ezetimibe | 29 | 12 |
| Glimepiride | Glimepiride | 29 | 11 |
| Mupirocin | Mupirocin | 28 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Xifaxan | Rifaximin | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 18 |
| Fluconazole | Fluconazole | 23 | 15 |
| Jardiance | Empagliflozin | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $46.45 · 3 records | PBG PUERTO RICO LLC | Auvelity, JARDIANCE, VYNDAQEL | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error